SCHEMBL1665817

SCHEMBL1665817

CCNC(C)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16821953 0.78 SIGMAR1 (0.31)
SCHEMBL3400008 0.75
SCHEMBL23878223 0.73
SCHEMBL2058389 0.73
SCHEMBL21620810 0.73
SCHEMBL27341141 0.73
SCHEMBL11073718 0.73
SCHEMBL8327572 0.73
SCHEMBL3608 0.72
SCHEMBL1695836 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000107-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2015-04-07 US claimed
US-20120196995-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2012-08-02 US claimed
US-4087245-A Process for the preparation of concentrated solutions of anionic dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1978-05-02 US claimed
EP-2753618-B1 HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2018-04-11 EP disclosed
US-9000107-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2015-04-07 US disclosed
US-8648072-B2 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes JENRIN DISCOVERY, INC. (US) 2014-02-11 US disclosed
US-20120264754-A1 CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES JENRIN DISCOVERY (US) 2012-10-18 US disclosed
US-20120196995-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2012-08-02 US disclosed
US-8217038-B2 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes JENRIN DISCOVERY, INC. (US) 2012-07-10 US disclosed
US-20110257178-A1 CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES JENRIN DISCOVERY (US) 2011-10-20 US disclosed
WO-2011044370-A1 CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES JENRIN DISCOVERY (US) 2011-04-14 WO disclosed
WO-2002050041-A1 DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-27 WO disclosed
US-20020068753-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. 2002-06-06 US disclosed
WO-2002036584-A1 CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-10 WO disclosed
WO-2002020483-A1 PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-03-14 WO disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 WO disclosed
CN-1037175-C Halomethylbenzoyl cyanides and process for preparing same BASF AG (DE) 1998-01-28 CN disclosed
CN-1097412-A Preparation of halomethylbenzoyl cyanides and novel halomethylbenzoyl cyanides BASF AG (DE) 1995-01-18 CN disclosed
US-4087245-A Process for the preparation of concentrated solutions of anionic dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1978-05-02 US disclosed
US-4058517-A Preparation of a concentrated solution of an anionic azo dye containing a sulfonic acid group BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) 1977-11-15 US disclosed